


PATENT/Docket No. PC10901A
 Appl. No. 09/779,413
 Filing Date: February 8, 2001
 Response dated October 1, 2004
 Response to Office Action of July 29, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A method for the treatment ~~or prophylaxis~~ of an endothelin-mediated disorder in a companion animal which comprises administering an effective amount, wherein the free blood plasma concentration after twenty four hours remains above the concentration providing efficacy for said endothelin-mediated disorder, of a compound of formula I or a veterinarily acceptable salt thereof to the companion animal, compound of formula 1 having the formula:



wherein R¹ and R² each represent H, or together represent a second carbon-carbon bond between the carbon atoms to which they are attached;

when R¹ and R² each represent H, then R³ and R⁴ also represent H;

when R¹ and R² together represent a second carbon-carbon bond between the carbon atoms to which they are attached, then R³ and R⁴ independently represent H or C₁-C₆ alkyl;

Ar represents:

phenyl or naphthyl, which groups are optionally substituted by one or more groups selected from C₁-C₆ alkyl ~~(which may itself be substituted by one or more substituents selected~~

PATENT/Docket No. PC10901A

Appl. No. 09/779,413

Filing Date: February 8, 2001

Response dated October 1, 2004


Response to Office Action of July 29, 2004

~~from halo, C₁-C₆ alkoxy, CO₂H, NH₂, NH(C₁₋₆ alkyl) and N((C₁₋₆ alkyl)₂), halo, C₁₋₆ alkoxy, CO₂H, C₁₋₆ alkoxycarbonyl, NO₂, CN, NH₂, NH(C₁₋₆ alkyl), N(C₁₋₆ alkyl)₂-OH and C₁₋₃ alkylendioxy and CF₃, or~~

~~— a 5- or 6-membered heteroaryl ring containing up to 4 heteroatoms selected from N, O and S, which group is optionally substituted by one or more groups selected from C₁₋₆ alkyl, halo, C₁₋₆ alkoxy, CO₂H, C₁₋₆ alkoxycarbonyl, NO₂, CN, NH₂, NH(C₁₋₆ alkyl), and N(C₁₋₆ alkyl)₂.~~

2. (Previously presented) A method according to claim 1, wherein the companion animal is a cat, a dog or a horse.
3. (Previously presented) A method according to claim 1 or 2, wherein the endothelin mediated disorder is hypertension, congestive heart failure or chronic renal failure.
4. (Previously presented) A method according to claim 1, wherein R¹ and R² each represent H.
5. (Previously presented) A method according to claim 1, wherein R³ and R⁴ each represent H.
6. (Canceled)
7. (Previously presented) The method according to claim 1, wherein Ar is phenyl.
8. (Previously presented) The method of claim 1, wherein the endothelin mediated disorder is congestive heart failure.
9. (Previously presented) The method of claim 1, wherein the endothelin mediated disorder is chronic renal failure.
10. (Currently amended) A formulation containing a compound of formula I or a veterinarily acceptable salt thereof:

PATENT/Docket No. PC10901A
 Appl. No. 09/779,413
 Filing Date: February 8, 2001
 Response dated October 1, 2004
 Response to Office Action of July 29, 2004



wherein R^1 and R^2 each represent H, or together represent a second carbon-carbon bond between the carbon atoms to which they are attached;

when R^1 and R^2 each represent H, then R^3 and R^4 also represent H;

when R^1 and R^2 together represent a second carbon-carbon bond between the carbon atoms to which they are attached, then R^3 and R^4 independently represent H or C_1 - C_6 alkyl;

Ar represents:

phenyl or naphthyl, which groups are optionally substituted by one or more groups selected from C_1 - C_6 alkyl (which may itself be substituted by one or more substituents selected from halo, C_1 - C_6 alkoxy, CO_2H , NH_2 , $NH(C_1$ - C_6 alkyl) and $N((C_1$ - C_6 alkyl) $_2$), halo, C_1 - C_6 alkoxy, CO_2H , C_1 - C_6 alkoxy carbonyl, NO_2 , CN , NH_2 , $NH(C_1$ - C_6 alkyl), $N(C_1$ - C_6 alkyl) $_2$ OH and C_{1-3} alkylenedioxy and CF_3 , or

~~a 5- or 6-membered heteroaryl ring containing up to 4 heteroatoms selected from N, O and S, which group is optionally substituted by one or more groups selected from C_1 - C_6 alkyl, halo, C_1 - C_6 alkoxy, CO_2H , C_1 - C_6 alkoxy carbonyl, NO_2 , CN , NH_2 , $NH(C_1$ - C_6 alkyl), and $N(C_1$ - C_6 alkyl) $_2$;~~

the formulation characterized in that it is suitable for administration to a companion animal, wherein the free blood plasma concentration of compound of formula 1 after twenty four hours remains above the concentration providing efficacy for said endothelin-mediated disorder.

11. (Previously presented) A formulation according to claim 10, which is suitable for oral administration to the companion animal.

12-14. (Canceled)

PATENT/Docket No. PC10901A
Appl. No. 09/779,413
Filing Date: February 8, 2001
Response dated October 1, 2004
Response to Office Action of July 29, 2004

15. (New) A method according to claim 1 wherein the compound of formula 1 is N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-phenylethanesulfonamide.
16. (New) A method according to claim 1 wherein the compound of formula 1 is N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-phenylethanesulfonamide.
17. (New) A formulation according to claim 10 wherein the compound of formula 1 is N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-phenylethanesulfonamide.
18. (New) A formulation according to claim 10 wherein the compound of formula 1 is N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-phenylethanesulfonamide.